STAT

OCTOBER 24, 2023

But when it comes to what is arguably the hottest space in drug development today — controlling weight and diabetes for millions of people worldwide — the brainy innovators from Kendall Square have missed out on the booming market, at least so far.

Diabetes 264

Diabetes Drug Development 264

Pharmaceutical Technology

OCTOBER 25, 2022

BioMed X has entered a research partnership with Sanofi to leverage artificial intelligence (AI) for drug development. This team will focus on creating a versatile computational platform that can precisely forecast the first-in-class drug candidates’ efficacy in virtual patient groups.

Drug Development 98

Drug Development Diabetes Immunity Immunization 98

STAT

APRIL 12, 2024

Enjoy, and see you soon… Western drug makers are talking to alternative suppliers in response to draft U.S. legislation seeking to restrict an important Chinese drug developer and manufacturer over national security concerns , The Financial Times explains. But be safe. The Biosecure Act would prohibit U.S.

Drug Development 256

Drug Development Diabetes Drug Pricing 256

PharmaShots

APRIL 10, 2023

Shots: With an incurable nature and hefty medication costs, diabetes mellitus remains a global health concern and the seventh leading cause of death across the world. Diabetes, aka diabetes mellitus is a condition that arises when the pancreas fails to produce enough insulin or the cells of the body do not respond to the insulin produced.

Diabetes 40

Diabetes Biosimilars Pharmaceutical Companies Pharmaceutical Companies 40

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. According to GlobalData, Phase III drugs for Type 2 Diabetes have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Diabetes 72

Diabetes Drug Development 72

pharmaphorum

AUGUST 25, 2022

Obesity, diabetes, and genetics are the primary drivers, and COVID is about to make this exponentially worse. Dozens of companies are working at various stages of drug development. The post Fatty liver disease: With little early detection, more challenging drug development appeared first on. About the Author.

Drug Development 98

Drug Development Diabetes 98

STAT

OCTOBER 17, 2023

Her team had failed to wrestle a gut hormone called GLP-1 into a new kind of drug for diabetes. Thomsen got right to the point. Management was giving them one more shot. And by them, he meant her. “You need to figure out what to do with GLP-1,” he said. “And it has to be now.”

Diabetes 354

Diabetes Drug Development 354

STAT

JUNE 27, 2023

But Eli Lilly has been following close behind with new treatments, and after dropping result after result from successful trials at the American Diabetes Association conference here this past weekend, the Indianapolis-based drugmaker looks to be gaining an edge over its Danish competitor in the race to supply obesity drugs.

Diabetes 252

Diabetes Drug Development 252

STAT

DECEMBER 11, 2023

And before the end of the month, Vertex will share results from a mid-stage trial in people with diabetes who have chronic nerve pain. The company will announce data early next year from Phase 3 studies testing the molecule’s effectiveness at treating post-surgical pain.

Diabetes 357

Diabetes Drug Development 357

STAT

JUNE 23, 2023

The full   results,  published Friday in the New England Journal of Medicine, were presented here to a packed conference room at the American Diabetes Association conference. The mid-stage results for orforglipron match the estimates of 14-15% weight loss that Lilly gave in an investor call late last year.

Diabetes 265

Diabetes Drug Development 265

PharmExec

OCTOBER 31, 2023

Collaboration aims to expand space research in studies of heart disease and diabetes.

Drug Development 52

Drug Development Diabetes 52

PharmExec

OCTOBER 31, 2023

Collaboration aims to expand space research in studies of heart disease and diabetes.

Drug Development 52

Drug Development Diabetes 52

STAT

JANUARY 12, 2024

Food and Drug Administration did not find evidence that GLP-1 drugs like Ozempic and Wegovy cause suicidal thoughts or actions , STAT notes. Novartis backed away from its pursuit of Cytokinetics, putting a damper on the prospects of a deal for the promising heart-drug developer , The Wall Street Journal reports.

Diabetes 276

Diabetes Drug Development 276

STAT

OCTOBER 27, 2023

The plan is to increase investment in its drug-development pipeline and cut costs, and the split could take place as early as the fourth quarter of 2024. The panel committee reviewed non-clinical, clinical, and post-marketing data of the drugs, and said that no updates to their prescribing information was required at the time.

Diabetes 281

Diabetes Drug Development 281

STAT

JUNE 26, 2023

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Diabetes 253

Diabetes Drug Development 253

STAT

MAY 22, 2023

A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus. Novo Nordisk said it plans to submit oral semaglutide for U.S. approvals later this year. Continue to STAT+ to read the full story…

Diabetes 246

Diabetes Drug Development 246

Pharma Mirror

JANUARY 24, 2023

Science-based innovation for manufacturing high quality cells challenges dogma and terminology Cell and gene therapies are dominating the world of drug development. billion by 2026, up from $186 billion in 2019 according to the Evaluate Pharma report.

Diabetes 52

Diabetes Drug Development 52

PharmaTech

AUGUST 3, 2023

You’ll explore their applications in various medical fields, such as CNS disorders, cancers, diabetes, substance abuse, eye diseases, HIV treatment and prevention, and contraception.

Diabetes 52

Diabetes Drug Development 52

Express Pharma

APRIL 17, 2024

Biopharmaceutical companies are regaining interest in metabolic dysfunction-associated steatohepatitis (MASH) innovator drug development. MASH innovator drugs witnessed over $2.5

Drug Development 78

Drug Development Diabetes 78

Pharmaceutical Technology

JUNE 5, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetes 52

Diabetes Drug Development 52

Pharmaceutical Technology

DECEMBER 16, 2022

Sosei Heptares and Eli Lilly and Company have signed a partnership for the discovery, development and commercialisation of small molecules that modulate new G protein-coupled receptor (GPCR) targets linked to diabetes and metabolic diseases.

Diabetes 52

Diabetes Drug Development 52

European Pharmaceutical Review

NOVEMBER 9, 2023

Following her presentation on age-related disease at BioFuture 2023, Executive Vice President of Drug Development for MyMD Pharmaceuticals ® , Jenna Brager, shares with EPR why the company’s next-generation tumour necrosis factor (TNF)-alpha inhibitor has potential in inflammatory and autoimmune disorders.

Drug Development 104

Drug Development Immunity Immunization Pharmaceutical Companies 104

Pharmaceutical Technology

FEBRUARY 23, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Biosimilars 52

Biosimilars Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. The nomination of a first candidate in the collaboration that will advance into development triggers a $2.5

Diabetes 66

Diabetes Drug Development 66

European Pharmaceutical Review

JULY 25, 2023

Rising demand for affordable and accessible drugs in regions like Asia-Pacific, Latin America, and Africa can offer potential for manufacturers in this sector to become established in these markets and work on their drug development. This opportunity can lead to higher production and revenue, the research reported.

Compounding 77

Compounding Generic Medicine Drug Development Diabetes 77

Pharmaceutical Technology

MAY 19, 2023

This value-creating transaction has enabled EyePoint to pay off all outstanding bank debt at closing, reduce our projected selling, general and administrative spending and extend our cash runway into 2025 as we prepare for the potential Phase III pivotal trials for EYP-1901.”

Diabetes 52

Diabetes Drug Development 52

Pharmaceutical Technology

MAY 31, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetes 52

Diabetes Immunity Immunization Hospitals 52

pharmaphorum

JANUARY 17, 2022

The drug, developed by Incyte and licenced to Lilly, is also used to treat rheumatoid arthritis. US-based Eli Lilly’s baricitinib (Olumiant), a Janus kinase inhibitor, and GlaxoSmithKline and Vir Biotechnology’s sotrovimab, a monoclonal antibody, were recommended in new WHO guidelines, published in the British Medical Journal. .

Hospitals 116

Hospitals Diabetes Immunity Immunization 116

Express Pharma

JULY 3, 2023

How is the industry’s approach to drug development transforming? How is Waters aiding advancements in drug development? A central aim in drug development is to create new molecular entities into commercially viable drugs useful in managing diseases. What are the imperatives that led to this change?

Biosimilars 79

Biosimilars Drug Development Generic Medicine Diabetes 79

pharmaphorum

JUNE 24, 2021

Lucentis has been approved by the FDA since 2006 for wet AMD and is a big earner for both Roche and Novartis, who share rights to the product with Roche selling the drug in the US and Novartis selling it in Europe and other markets. Wet AMD is a leading cause of blindness for people aged 60 and over and affects approximately 1.1

Diabetes 95

Diabetes Biosimilars Drug Development 95

Pharmaceutical Technology

JUNE 5, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetes 40

Diabetes Drug Development 40

Pharmaceutical Technology

JUNE 5, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetes 40

Diabetes Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetes 40

Diabetes Drug Development 40

Pharmaceutical Technology

JUNE 10, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Diabetes 40

Diabetes Drug Development 40

Pharmaceutical Technology

MARCH 1, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Diabetes 40

Pharmaceutical Technology

MARCH 1, 2023

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies Drug Development Diabetes 40

Pharmaceutical Technology

MARCH 1, 2023

Recent breakthroughs in the development of RNA therapeutics have expanded their utility across a wide range of applications, from intravenous (IV) delivery directly into tumours for enhanced cancer therapy, to improving structural stability and purity using novel computational modelling.

Vaccines 59

Vaccines Drug Development Diabetes 59